Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-301 and CDX-1140 in Resectable Pancreatic Cancer
NCT04536077Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Flt3 ligand, CDX-1140 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Washington University School of Medicine. Started Aug 2021; status: terminated.
02
Drugs
Flt3 ligandCDX-1140
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04536077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536077.